NCT04449861

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 166 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.

Conditions

• Small Cell Lung Carcinoma Extensive Disease

Interventions

Type	Name	Description
DRUG	Durvalumab plus chemotherapy	Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria. Drug: Carboplatin 4-6 cycles every 3 weeks Drug: Cisplatin 4-6 cycles every 3 weeks Drug: Etoposide 4-6 cycles every 3 weeks

Timeline

• Start date: 2020-12-07
• Primary completion: 2023-03-30
• Completion: 2023-03-30
• First posted: 2020-06-29
• Last updated: 2024-11-27
• Results posted: 2024-11-27

Locations

30 sites across 1 country: China